NK cells require IL-28R for optimal in vivo activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 18, 2015, Pages E2376-E2384

  Souza Fonseca Guimaraes, Fernando ^a,b   Young, Arabella ^a,b   Mittal, Deepak ^a   Martinet, Ludovic ^a   Bruedigam, Claudia ^a   Takeda, Kazuyoshi ^c   Andoniou, Christopher E ^d,e   Degli Esposti, Mariapia A ^d,e   Hill, Geoffrey R ^a,f   Smyth, Mark J ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c JUNTENDO UNIVERSITY   (Japan)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e LIONS EYE INSTITUTE   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Anti tumor; IL 28R; Interferon; LPS; NK cells

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 28; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; CARCINOGEN; CYTOKINE; CYTOKINE RECEPTOR; ENDOTOXIN; INTERFERON; INTERLEUKIN 28ALPHA RECEPTOR; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOMA; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEPTIC SHOCK; ANIMAL; C57BL MOUSE; CELL SEPARATION; CYTOLOGY; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION REGULATION; KNOCKOUT MOUSE; MALE; METABOLISM; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; CARCINOGENS; CELL SEPARATION; CYTOKINES; ENDOTOXINS; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION REGULATION; INTERFERON TYPE I; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM METASTASIS; RECEPTORS, CYTOKINE; RNA, MESSENGER; SHOCK, SEPTIC; SIGNAL TRANSDUCTION;

EID: 84928969460     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424241112     Document Type: Article

References (58)

1. Kotenko SV, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
2. Sheppard P, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63-68.
3. Jewell NA, et al. (2010) Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 84(21):11515-11522.
4. Prokunina-Olsson L, et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45(2):164-171.
5. Donnelly RP, Kotenko SV (2010) Interferon-lambda: A new addition to an old family. J Interferon Cytokine Res 30(8):555-564.
6. Zhou Z, et al. (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81(14):7749-7758.
7. Iversen MB, Paludan SR (2010) Mechanisms of type III interferon expression. J Interferon Cytokine Res 30(8):573-578.
8. Degli-Esposti MA, Smyth MJ (2005) Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nat Rev Immunol 5(2):112-124.
9. Chan CJ, Smyth MJ, Martinet L (2014) Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ 21(1):5-14.
10. Street SE, Cretney E, Smyth MJ (2001) Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97(1):192-197.
11. Swann JB, et al. (2007) Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 178(12):7540-7549.
12. Souza-Fonseca-Guimaraes F, Adib-Conquy M, Cavaillon JM (2012) Natural killer (NK) cells in antibacterial innate immunity: angels or devils? Mol Med 18:270-285.
13. Souza-Fonseca-Guimaraes F, Cavaillon JM, Adib-Conquy M (2013) Bench-to-bedside review: Natural killer cells in sepsis - guilty or not guilty? Crit Care 17(4):235.
14. Marcello T, et al. (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6):1887-1898.
15. Mordstein M, et al. (2008) Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4(9): e1000151.
16. Robek MD, Boyd BS, Chisari FV (2005) Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79(6):3851-3854.
17. Numasaki M, et al. (2007) IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 178(8):5086-5098.
18. Lasfar A, et al. (2006) Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66(8):4468-4477.
19. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176(12):7686-7694.
20. Abushahba W, et al. (2010) Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 59(7):1059-1071.
21. Ank N, et al. (2008) An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180(4):2474-2485.
22. Kim M, et al. (2012) Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes. J Immunol 188(9): 4158-4170.
23. Dring MM, et al.; Irish HCV Research Consortium (2011) Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci USA 108(14):5736-5741.
24. Gardiner CM, Morrison MH, Dring MM(2011) Human natural killer (NK) cell inhibition by IL28A. Proc Natl Acad Sci USA 108(34):E521-E522 (lett).
25. Krueger PD, Lassen MG, Qiao H, Hahn YS (2011) Regulation of NK cell repertoire and function in the liver. Crit Rev Immunol 31(1):43-52.
26. Vivier E, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44-49.
27. Hayakawa Y, Smyth MJ (2006) CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 176(3):1517-1524.
28. Chan CJ, et al. (2014) The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 15(5):431-438.
29. Anthony DA, et al. (2010) A role for granzyme M in TLR4-driven inflammation and endotoxicosis. J Immunol 185(3):1794-1803.
30. Andrews DM, et al. (2011) Homeostatic defects in interleukin 18-deficient mice contribute to protection against the lethal effects of endotoxin. Immunol Cell Biol 89(6): 739-746.
31. Ganal SC, et al. (2012) Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 37(1): 171-186.
32. Romero CR, et al. (2010) The role of interferon-γ in the pathogenesis of acute intra-abdominal sepsis. J Leukoc Biol 88(4):725-735.
33. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA (2009) Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 4(1):31-36.
34. Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER (2008) NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J Immunol 180(9):6334-6345.
35. Sathe P, et al. (2014) Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun 5:4539.
36. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D (2003) Cytokine cascade in sepsis. Scand J Infect Dis 35(9):535-544.
37. Flierl MA, et al. (2008) Adverse functions of IL-17A in experimental sepsis. FASEB J 22(7):2198-2205.
38. Bär E, Whitney PG, Moor K, Reis e Sousa C, LeibundGut-Landmann S (2014) IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40(1):117-127.
39. Craciun FL, Schuller ER, Remick DG (2010) Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival. J Immunol 185(11):6930-6938.
40. Sumaria N, et al. (2009) The roles of interferon-gamma and perforin in antiviral immunity in mice that differ in genetically determined NK-cell-mediated antiviral activity. Immunol Cell Biol 87(7):559-566.
41. Teng MW, von Scheidt B, Duret H, Towne JE, Smyth MJ (2011) Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. Cancer Res 71(6):2077-2086.
42. Chow MT, et al. (2012) NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res 72(22):5721-5732.
43. Smyth MJ, Kelly JM, Baxter AG, Körner H, Sedgwick JD (1998) An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 188(9):1611-1619.
44. Cao X, et al. (2007) Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27(4):635-646.
45. Swann JB, et al. (2008) Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 105(2): 652-656.
46. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011) Interferon lambda: A new sword in cancer immunotherapy. Clin Dev Immunol 2011:349575.
47. Mlecnik B, et al. (2014) Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 6(228):228ra237.
48. Huntington ND, Vosshenrich CA, Di Santo JP (2007) Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 7(9): 703-714.
49. Witte K, et al. (2009) Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: Implications for therapeutic applications of these cytokines. Genes Immun 10(8):702-714.
50. Marçais A, et al. (2013) Regulation of mouse NK cell development and function by cytokines. Front Immunol 4:450.
51. Brady J, et al. (2010) The interactions of multiple cytokines control NK cell maturation. J Immunol 185(11):6679-6688.
52. Ferrantini M, Capone I, Belardelli F (2007) Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie 89(6-7):884-893.
53. Moschos S, Kirkwood JM (2007) Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev 18(5-6):451-458.
54. Dunn GP, et al. (2005) Interferon-gamma and cancer immunoediting. Immunol Res 32(1-3):231-245.
55. Li Q, et al. (2010) Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 46(1):180-190.
56. Allard B, Pommey S, Smyth MJ, Stagg J (2013) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19(20):5626-5635.
57. Teng MW, et al. (2010) IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci USA 107(18):8328-8333.
58. Lindberg J, Martín-Fontecha A, Höglund P (1999) Natural killing of MHC class I(-) lymphoblasts by NK cells from long-term bone marrow culture requires effector cell expression of Ly49 receptors. Int Immunol 11(8):1239-1246.